F4 FundFund
TeamPortfolioRaiseEssays
Sign in
Investment ThesisInvestment TeamF4 Research BriefSelected PortfolioRecent UpdatesFrequent co-investors
Active Fund

HealthQuest Capital

healthquestcapital.com

Investment thesis

Growth capital for commercial-stage companies transforming healthcare, across services, healthcare IT, medical devices, diagnostics and pharma services.

Leads
Lead Tendency
$2B
AUM
01Investment Thesis

Growth capital for commercial-stage companies transforming healthcare, across services, healthcare IT, medical devices, diagnostics and pharma services.

02Investment Team
GK
Garheng Kong
Founding Managing Partner
RS
Randy Scott
Founding Partner
DK
David Kabakoff
Founding Senior Partner
SB
Sam Brasch
Partner
SR
Sharath Reddy
Partner
NB
Nate Burns
Partner
WM
Witney McKiernan
Partner
JT
Jared Teo
Managing Director, Investment Execution
NP
Neil Parikh
Principal
EZ
Emily Zhen
Principal
BG
Bill Gerard
Vice President
KS
Katie Shi
Senior Associate
03F4 Research Brief

HealthQuest Capital Research

Investment Thesis

HealthQuest Capital is a healthcare-only growth investor founded in 2012. It provides growth capital to commercial-stage companies that are transforming healthcare, and says it looks for businesses that improve patient outcomes and raise the efficiency of healthcare delivery. The firm describes its approach as investing at the intersection of healthcare subsectors, across both newer delivery models and traditional approaches. Its stated mission is to contribute to broadly improving people's lives through healthcare innovation while generating outsized risk-adjusted returns for its stakeholders.

Stage Focus

HealthQuest focuses primarily on commercial-stage companies that are ready to scale. It runs two strategies, Growth Equity and Tactical Opportunities, which let it use a range of structures tailored to each company. It is not a pre-seed or seed fund. Founders should expect to show commercial traction before approaching the firm.

Check Size

HealthQuest does not publish a check size range. Its flagship Fund IV closed at $675 million in May 2022, and the firm reports roughly $2 billion in assets under management across 52 portfolio companies, so its positions are growth-sized rather than early-stage checks.

Sector Focus

The firm invests across the healthcare landscape:

  • Healthcare services
  • Healthcare IT
  • Medical devices
  • Diagnostics
  • Pharma services

The portfolio spans value-based care and chronic care (Somatus, Thyme Care, CopilotIQ, Inbound Health), medical technology (HistoSonics, OrganOx, Pulmonx, Trice Medical, Magnolia Medical Technologies), diagnostics and life-science tools (Rarecyte, Perspectum, Lunit), telehealth and consumer health (Amwell, Everly Health, Remedy Meds, Thirty Madison), and provider platforms (American Oncology Network, ENT Specialty Partners).

Lead Tendency

HealthQuest backs companies with significant capital and operating support, and it has led rounds, including a $142 million equity financing in February 2025. It describes itself as an active partner rather than a spectator of its portfolio.

Recent Activity

The firm has had a strong run of exits. In 2025, Terumo agreed to acquire OrganOx (August), HistoSonics was acquired by a consortium of investors at a $2.25 billion valuation (August), Remedy Meds agreed to acquire Thirty Madison (September), and Truven acquired Springbuk (September). In November 2024, Boston Scientific agreed to acquire Cortex. HealthQuest reports 23 total exits. Managing Partner Garheng Kong was named among the top healthcare investors of 2025 by GrowthCap.

Portfolio Highlights

  • HistoSonics, acquired in 2025 at $2.25 billion
  • OrganOx, being acquired by Terumo
  • Thirty Madison, being acquired by Remedy Meds
  • Amwell, Castle Biosciences and Lunit, which reached public markets
  • Current holdings include 83bar, Ajax Health, Alcresta Therapeutics, CopilotIQ, Everly Health, Somatus, Thyme Care and Tiger Connect

Team

The investment team is led by a mix of physicians, scientists and operators.

  • Garheng Kong, Founding Managing Partner
  • Randy Scott, Founding Partner
  • David Kabakoff, Founding Senior Partner
  • Sam Brasch, Partner
  • Sharath Reddy, Partner
  • Nate Burns, Partner
  • Witney McKiernan, Partner
  • Jared Teo, Managing Director, Investment Execution
  • Neil Parikh and Emily Zhen, Principals

The firm cites more than 300 years of combined operating and investing experience. It also works with operating partners, an Industry Advisory Board of former healthcare executives (including former CEOs of Becton Dickinson, Medtronic, Cardinal Health and LabCorp) and a Healthcare IT Council of health-system technology leaders.

Decision Process

HealthQuest makes decisions as a partnership. Its investment team works with its advisory boards on diligence and company support.

Founder Preferences

The firm looks for commercially proven healthcare companies with a path to scale, where its network of health-system, payer and employer relationships can help expand market presence. It cites reach of about 104 million patients, more than 3,000 hospital partners and about 6,500 employer partners across its portfolio.

Geographic Focus

HealthQuest invests across the United States and has backed companies in Europe and Asia, including OrganOx in the UK, Perspectum in the UK and Lunit in South Korea. It does not publish a geographic restriction.

04Selected Portfolio
Biotech & Life Sciences
Ajax Health·Alpheus Medical·Eyconis·HistoSonics·RareCyte·Avedro·Bio Theranostics·Castle Biosciences·Lineagen·OrganOx
Developer Tools & Infrastructure
Cortex
Enterprise Software
AnswersNow·Clean Slate
Healthcare & Digital Health
83bar·Alcresta Therapeutics·American Oncology Network·Care Connectors·Clearsense·Connie Health·CopilotIQ·Diana Health·ENT Specialty Partners·Endpoint·Etairos Health·Everlywell·HelloCare·Magnolia Medical·Metro Vein·Neovance·Perspectum·Pulmonx·Remedy Meds·Royal Health·Scribe America·Somatus·Thyme Care·TigerConnect·Trice Medical·Venus·Amwell·Avizia·BardyDx·BioIQ·CareMetx·Inbound Health·Inmediata·Lunit·Springbuk·Thirty Madison
Semiconductors & Hardware
Spirox
Open the full portfolio→
05Recent Updates

Fresh signals from public announcements, essays, and portfolio activity.

See full activity (7) →
Truven acquired portfolio company Springbuk, an employer healthcare analytics provider.
EXIT·healthquestcapital.com
SEP 10, 2025
Portfolio company Remedy Meds agreed to acquire Thirty Madison, another portfolio company.
EXIT·healthquestcapital.com
SEP 3, 2025
Terumo agreed to acquire portfolio company OrganOx, an organ preservation device maker.
EXIT·healthquestcapital.com
AUG 25, 2025
Portfolio company HistoSonics announced a $2.25B acquisition by a consortium of investors.
EXIT·healthquestcapital.com
AUG 7, 2025
Garheng Kong was named among the top healthcare investors of 2025 by GrowthCap.
NEWS·growthcapadvisory.com
MAY 5, 2025
06Frequent co-investors
A
Alleycorp
Both backed 2 of the same companies
Thyme Care, Diana Health
BV
Blue Venture Fund
Both backed 2 of the same companies
Somatus, Perspectum
CH
Corewell Health Ventures
Both backed 2 of the same companies
Thyme Care, TigerConnect
CV
CVS Ventures
Both backed 2 of the same companies
Thyme Care, Thirty Madison
LV
Lumira Ventures
Both backed 2 of the same companies
HistoSonics, BardyDx
Find the investors for your round→
Quick Reference
Stages
Growth
AUM
$2B
Decision
Partnership
Sector Focus
Biotech & Life SciencesHealthcare & Digital Health
Models
Healthcare ServicesHealthcare ITMedical DevicesDiagnosticsPharma Services
See all Biotech & Life Sciences investors →See all Healthcare & Digital Health investors →
Visit healthquestcapital.com ↗

See how HealthQuest Capital matches your startup

Get a personalized match report in minutes.

Get Your Match Report
Focus Areas
Biotech & Life SciencesHealthcare & Digital Health

See how HealthQuest Capital matches your startup

Get a personalized match report in minutes.

Get Your Match Report
Is this your firm? Claim your profile
F4 Intelligence Report · Last Researched November 21, 2026F4 Research Engine